Setmelanotide (Imcivree) for Rare Genetic Forms of Obesity (online only)

Date: July 26, 2021
Issue #: 
1629Summary: 
The FDA has approved setmelanotide (Imcivree–
Rhythm), a subcutaneously injected melanocortin 4
(MC4) receptor agonist, for chronic weight management
in patients ≥6 years old with obesity due to
pro-opiomelanocortin (POMC) deficiency, proprotein
subtilisin/kexin type 1 (PCSK1) deficiency, or leptin
receptor (LEPR) deficiency.

Source: The Medical Letter - July 14, 2021 Category: Drugs & Pharmacology Authors: admin Source Type: research